Protocol kidney biopsy in the management of proliferative (class III/IV) lupus nephritis: barking up the wrong tree!

Clicks: 18
ID: 327666
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #98 of 152 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 152 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Lupus nephritis represents one of the most severe manifestations of systemic lupus erythematosus. Despite major advances in the therapeutical armamentarium over the last two decades, the number of patients reaching end stage kidney disease or dying has not changed significantly. One of the main reasons is that many patients relapse, and with each relapse, further damage is done to the kidney, contributing to the development of progressive chronic kidney disease. This has led to the increased practice of doing protocol biopsy to guide decision regarding risk for relapses and/or discontinuation of immunosuppression. However, this practice has been based on the assumption that the answer is in the kidney, while in reality the kidney reflects the downgrade effect of what is going on upstream, i.e. the immunological milieu. We provide an in-dept review on the use of repeat protocol kidney biopsies in LN with the hope to demonstrate that this practice is based on faulty evidence and of limited benefit in the management of patients with proliferative class III/IV lupus nephritis. Rather, physicians treating these patients should focus on markers of immunological activity (anti-ds-DNA levels) and clinical activity (C3/C4 complement levels), to better predict risk for relapses and in deciding when to reduce/discontinue immunosuppression. As such, this review represents a paradigm shift in the approach of evaluating activity in patients with LN, that is not done by performing protocol kidney biopsies, but rather by looking at the serological activity instead, and as such proposing a new vision on the subject that we believe will improve patient care and kidney outcomes.
Reference Key
openalex_W7208774233 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ladan Zand, Gian Marco Berti, Anila Cara, Sanjeev Sethi, Fernando C. Fervenza
Are you one of these authors? Claim your profile
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag207
URL
https://doi.org/10.1093/ndt/gfag207
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.